One clinical trial each: the question, the design, the numbers with an original chart, how far they can be trusted, and what changed in practice. Written for cardiology fellows.
- ACCOAST (2013) faculty-reviewed
ACCOAST — prasugrel before angiography (pretreatment) vs prasugrel in the lab once PCI is planned, in NSTEMI
- PLATO (2009) faculty-reviewed
PLATO — ticagrelor vs clopidogrel in acute coronary syndromes, with or without ST elevation
- TRITON-TIMI 38 (2007) faculty-reviewed
TRITON-TIMI 38 — prasugrel vs clopidogrel in acute coronary syndromes with scheduled PCI
- ISAR-REACT 5 (2019) faculty-reviewed
ISAR-REACT 5 — a ticagrelor-based vs a prasugrel-based strategy in acute coronary syndromes with planned invasive evaluation
- TWILIGHT (2019) faculty-reviewed
TWILIGHT — ticagrelor alone vs ticagrelor plus aspirin after 3 months of dual therapy in high-risk PCI
- TICO (2020) faculty-reviewed
TICO — ticagrelor alone after 3 months vs 12 months of ticagrelor-based dual therapy in acute coronary syndrome
- MASTER DAPT (2021) faculty-reviewed
MASTER DAPT — stop dual antiplatelet therapy at one month vs continue it, in patients at high bleeding risk
- WOEST (2013) faculty-reviewed
WOEST — clopidogrel alone vs clopidogrel plus aspirin in patients on an oral anticoagulant undergoing PCI
- PIONEER AF-PCI (2016) faculty-reviewed
PIONEER AF-PCI — rivaroxaban-based regimens vs vitamin K antagonist triple therapy after PCI in atrial fibrillation
- AUGUSTUS (2019) faculty-reviewed
AUGUSTUS — apixaban vs vitamin K antagonist, and aspirin vs placebo, with a P2Y12 inhibitor in atrial fibrillation after ACS or PCI
- AFIRE (2019) faculty-reviewed
AFIRE — rivaroxaban alone vs rivaroxaban plus one antiplatelet in atrial fibrillation with stable coronary disease
- EPIC-CAD (2024) faculty-reviewed
EPIC-CAD — edoxaban alone vs edoxaban plus one antiplatelet in atrial fibrillation with stable coronary disease
- HOST-EXAM (2021) faculty-reviewed
HOST-EXAM — clopidogrel vs aspirin as long-term single antiplatelet therapy after DAPT and a drug-eluting stent
- DAPT Study (2014) faculty-reviewed
DAPT Study — continued thienopyridine vs placebo, both with aspirin, from 12 to 30 months after a drug-eluting stent
- DanGer Shock (2024) faculty-reviewed
DanGer Shock — microaxial flow pump plus standard care vs standard care alone in STEMI with cardiogenic shock
- DanGer Shock (2024) faculty-reviewed
DanGer Shock — microaxial flow pump plus standard care vs standard care alone in STEMI with cardiogenic shock
- SHOCK (1999) faculty-reviewed
SHOCK — emergency revascularization vs initial medical stabilization in acute MI with cardiogenic shock
- SHOCK (1999) faculty-reviewed
SHOCK — emergency revascularization vs initial medical stabilization in acute MI with cardiogenic shock
- CULPRIT-SHOCK (2017) faculty-reviewed
CULPRIT-SHOCK — culprit-lesion-only PCI vs immediate multivessel PCI in acute MI with cardiogenic shock and multivessel disease
- CULPRIT-SHOCK (2017) faculty-reviewed
CULPRIT-SHOCK — culprit-lesion-only PCI vs immediate multivessel PCI in acute MI with cardiogenic shock and multivessel disease
- IABP-SHOCK II (2012) faculty-reviewed
IABP-SHOCK II — intra-aortic balloon pump vs no balloon pump in acute myocardial infarction with cardiogenic shock
- IABP-SHOCK II (2012) faculty-reviewed
IABP-SHOCK II — intra-aortic balloon pump vs no balloon pump in acute myocardial infarction with cardiogenic shock
- ISAR-SHOCK (2008) faculty-reviewed
ISAR-SHOCK — Impella LP2.5 microaxial pump vs intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction
- ISAR-SHOCK (2008) faculty-reviewed
ISAR-SHOCK — Impella LP2.5 microaxial pump vs intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction
- IMPRESS (2017) faculty-reviewed
IMPRESS — Impella CP microaxial pump vs intra-aortic balloon pump in severe cardiogenic shock after acute myocardial infarction
- IMPRESS (2017) faculty-reviewed
IMPRESS — Impella CP microaxial pump vs intra-aortic balloon pump in severe cardiogenic shock after acute myocardial infarction
- ECLS-SHOCK (2023) faculty-reviewed
ECLS-SHOCK — early VA-ECMO plus usual care vs usual care alone in AMI with cardiogenic shock and planned revascularization
- ECLS-SHOCK (2023) faculty-reviewed
ECLS-SHOCK — early VA-ECMO plus usual care vs usual care alone in AMI with cardiogenic shock and planned revascularization
- ECMO-CS (2023) faculty-reviewed
ECMO-CS — immediate VA-ECMO vs early conservative therapy in rapidly deteriorating or severe cardiogenic shock
- ECMO-CS (2023) faculty-reviewed
ECMO-CS — immediate VA-ECMO vs early conservative therapy in rapidly deteriorating or severe cardiogenic shock
- HYPO-ECMO (2022) faculty-reviewed
HYPO-ECMO — moderate hypothermia vs normothermia in cardiogenic shock treated with VA-ECMO
- HYPO-ECMO (2022) faculty-reviewed
HYPO-ECMO — moderate hypothermia vs normothermia in cardiogenic shock treated with VA-ECMO
- STEMI-DTU (2026) faculty-reviewed
STEMI-DTU — microaxial pump unloading for 30 minutes before PCI vs immediate PCI in anterior STEMI WITHOUT cardiogenic shock
- STEMI-DTU (2026) faculty-reviewed
STEMI-DTU — microaxial pump unloading for 30 minutes before PCI vs immediate PCI in anterior STEMI WITHOUT cardiogenic shock
- SOAP II (2010) faculty-reviewed
SOAP II — dopamine vs norepinephrine as first-line vasopressor in shock of all causes (cardiogenic-shock subgroup)
- SOAP II (2010) faculty-reviewed
SOAP II — dopamine vs norepinephrine as first-line vasopressor in shock of all causes (cardiogenic-shock subgroup)
- OptimaCC (2018) faculty-reviewed
OptimaCC — epinephrine vs norepinephrine in cardiogenic shock after acute MI
- OptimaCC (2018) faculty-reviewed
OptimaCC — epinephrine vs norepinephrine in cardiogenic shock after acute MI
- DOREMI (2021) faculty-reviewed
DOREMI — milrinone vs dobutamine in cardiogenic shock
- DOREMI (2021) faculty-reviewed
DOREMI — milrinone vs dobutamine in cardiogenic shock
- COMMIT (2005) faculty-reviewed
COMMIT (metoprolol) — early IV then oral metoprolol vs placebo in acute MI, and the cardiogenic shock it caused
- COMMIT (2005) faculty-reviewed
COMMIT (metoprolol) — early IV then oral metoprolol vs placebo in acute MI, and the cardiogenic shock it caused
- ESCAPE (2005) faculty-reviewed
ESCAPE — pulmonary artery catheter-guided therapy vs clinical assessment alone in severe heart failure without shock
- ESCAPE (2005) faculty-reviewed
ESCAPE — pulmonary artery catheter-guided therapy vs clinical assessment alone in severe heart failure without shock
- COACT (2019) faculty-reviewed
COACT — immediate vs delayed coronary angiography in resuscitated cardiac arrest without STEMI (cardiac-arrest box; not a STEMI shock trial)
- COACT (2019) faculty-reviewed
COACT — immediate vs delayed coronary angiography in resuscitated cardiac arrest without STEMI (cardiac-arrest box; not a STEMI shock trial)
- TOMAHAWK (2021) faculty-reviewed
TOMAHAWK — immediate vs delayed or selective coronary angiography in resuscitated cardiac arrest without ST elevation (cardiac-arrest box; not a STEMI shock trial)
- TOMAHAWK (2021) faculty-reviewed
TOMAHAWK — immediate vs delayed or selective coronary angiography in resuscitated cardiac arrest without ST elevation (cardiac-arrest box; not a STEMI shock trial)